IRVINE, Calif., Nov. 3, 2016 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL) announces today that it will partner with a new high technology start-up company that is forming on January 16, 2017 and will manufacture new consumer electronics and medical products. The new start-up company will begin privately and is being formed by world-class business structure strategists and accountants. It will be positioned for the purpose of a potential IPO on NASDAQ or NYSE in the future. EPGL shareholders of record on January 16, 2017 will receive equity in the new company up to a percentage equal to their EPGL holdings on that date. Shareholders who make request for the gift equity at firstname.lastname@example.org will hold separate shares in both the new private company and EPGL which will continue as a publicly traded OTC Company. EPGL will continue status-quo as a premier technology R&D company in which Johnson & Johnson Vision Care, Inc. continues to hold first rights of purchase negotiations. The name of the new company and all further details will be made available in announcements to come in January 2017. About EP Global Communications, Inc. EP Global Communications, Inc. is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS). Safe Harbor Statement Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.